Business
Trevi Therapeutics Announces Third Quarter 2021 Financial Results and Business Update
Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Approximately 90% Enrolled, Top-Line Data Readout Expected First Half of 2022 Phase 2 CANAL (Chronic Cough in
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Approximately 90% Enrolled, Top-Line Data Readout Expected First Half of 2022\n Phase 2 CANAL (Chronic Cough in IPF) Actively Enrolling, Top-Line Data Readout Expected First Half of 2022\n Management to Host Conference Call at 4:30 pm ET\n\n\nNEW HAVEN, Conn., Nov. 10, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced financial results for the quarter ended September 30, 2021, as well as provided business updates.\n\n \n \n \n \n \n \n\n \nPruritus in PN (PRISM) Trial ~90% enrolled and top-line data readout expected 1H 2022\"We continue to execute on enrollment for both of our trials, with PRISM, our Phase 2b/3 in chronic pruritus in prurigo nodularis (PN) now being 90% enrolled. Haduvio is the most advanced oral compound in clinical development for both pruritus in PN and chronic cough in patients with idiopathic pulmonary fibrosis (IPF),\" said Jennifer L. Good, President and CEO of Trevi Therapeutics. \"With large commercial market opportunities in our first two indications, we are excited to conclude these trials and report topline data in the first half of 2022. The potential for indication expansion in both pruritus and chronic cough is significant, and we continue to focus on completing these trials while preparing for further clinical development, future regulatory filings, and the commercial launch of Haduvio. There continues to be a high unmet need in these two patient populations.\"\nKey Business Updates\nPhase 2b/3 PRISM trial of Haduvio for severe pruritus in patients with PN Approximately 90% of the planned 360 subjects have enrolled Approximately 90% of eligible subjects continued into the open label extension study Top-line data readout expected in the first half of 2022Phase 2 CANAL trial of Haduvio for chronic cough in patients with IPF Enrollment steadily progressing with top-line data readout expected in the first half of 2022Upcoming MeetingsThe Company plans to present at the following upcoming conferences:\nStifel 2021 Virtual Healthcare Conference, November 15-17, 2021 5th Annual Dermatology Drug Development Summit for Inflammatory Sk...